Kadimastem Ltd
TASE:KDST
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Kadimastem Ltd
Net Issuance of Debt
Kadimastem Ltd
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
K
|
Kadimastem Ltd
TASE:KDST
|
Net Issuance of Debt
₪382k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-42%
|
CAGR 10-Years
-20%
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Net Issuance of Debt
-$6.9m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
1%
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Net Issuance of Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Net Issuance of Debt
-$1.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Net Issuance of Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Net Issuance of Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Kadimastem Ltd
Glance View
Kadimastem Ltd. is a clinical-stage bio-pharmaceutical company engaging in the development of industrial regenerative medicine therapies based on differentiated cells derived from Human Embryonic Stem Cells to treat neurology-degenerative diseases. The Company’s technology enables the differentiation of stem cells into insulin secreting beta cells, as well as a range of neural cells (including Oligodendrocytes, Astrocytes). The firm produces islet-like clusters that show glucose-stimulated insulin secretion. In addition, the Company is partnering with pharmaceutical companies interested to screen potential drug compounds (hit-lead, lead optimization) on its stem-cell derived cells, primarily oligodendrocytes and astrocytes.
See Also
What is Kadimastem Ltd's Net Issuance of Debt?
Net Issuance of Debt
382k
ILS
Based on the financial report for Dec 31, 2024, Kadimastem Ltd's Net Issuance of Debt amounts to 382k ILS.
What is Kadimastem Ltd's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 10Y
-20%
Over the last year, the Net Issuance of Debt growth was -87%.
